PRIME-RAS-EXTENDED

NCT00364013 📎

Regimen

Experimental
Panitumumab + FOLFOX4
Control
FOLFOX4 alone

Population

Metastatic CRC, 1L; subgroup re-analysis extending RAS mutation status beyond KRAS exon 2 to all KRAS/NRAS exons (subgroup re-analysis: RAS-extended).

Key finding

1L mCRC pan-RAS-wt: panitumumab+FOLFOX4 vs FOLFOX4: mOS 26.0 vs 20.2 mo (HR 0.78, 95% CI 0.62-0.99, p=0.04); mPFS 10.8 vs 9.2 mo (HR 0.72, p=0.004); RAS-mut: mOS 15.6 vs 19.2 mo — panitumumab significantly REDUCED OS in RAS-mut patients (HR 1.25, 95% CI 1.02-1.55, p=0.04)

Source: PMID 24024839

Timeline

    Guideline citations

    • NCCN Colon (p.58)
    • NCCN Rectal (p.75)